After menopause and discontinuation of dopamine agonists, we recommend follow-up with clinical evaluation and measurement of prolactin levels every 6 months in the first year and pituitary MRI at 12 months or earlier if symptoms of tumor mass effect develop. Here, PRL is linked to neoplasm.